rain-10q_20220331.htm
false 2022 Q1 --12-31 0001724979 0.9260 2022-12-31 P90D P6M P12M P60D P30D P135D 2017-04-30 0.9260 P24M P5Y P8Y9M18D P8Y10M24D P8Y10M24D P7Y10M24D P6Y1M6D P6Y 0.016 0.017 1.120 1.121 P1Y4M24D P2Y4M24D 0001724979 2022-01-01 2022-03-31 xbrli:shares 0001724979 2022-04-28 iso4217:USD 0001724979 2022-03-31 0001724979 2021-12-31 iso4217:USD xbrli:shares 0001724979 rain:UndesignatedCommonStockMember 2022-03-31 0001724979 rain:UndesignatedCommonStockMember 2021-12-31 0001724979 us-gaap:NonvotingCommonStockMember 2022-03-31 0001724979 us-gaap:NonvotingCommonStockMember 2021-12-31 0001724979 2021-01-01 2021-03-31 0001724979 us-gaap:CommonStockMember 2021-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001724979 us-gaap:RetainedEarningsMember 2021-12-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001724979 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001724979 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001724979 us-gaap:CommonStockMember 2022-03-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001724979 us-gaap:RetainedEarningsMember 2022-03-31 0001724979 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2020-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-12-31 0001724979 us-gaap:CommonStockMember 2020-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001724979 us-gaap:RetainedEarningsMember 2020-12-31 0001724979 2020-12-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001724979 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2021-03-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2021-03-31 0001724979 us-gaap:CommonStockMember 2021-03-31 0001724979 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001724979 us-gaap:RetainedEarningsMember 2021-03-31 0001724979 2021-03-31 0001724979 rain:EmployeeStockPurchasePlanMember 2022-01-01 2022-03-31 rain:Segment xbrli:pure 0001724979 us-gaap:CommonStockMember 2021-04-16 2021-04-16 0001724979 us-gaap:CommonStockMember us-gaap:IPOMember 2021-04-27 2021-04-27 0001724979 us-gaap:CommonStockMember us-gaap:IPOMember 2021-04-27 0001724979 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2021-05-11 2021-05-11 0001724979 rain:IPOAndOverAllotmentOptionMember 2022-01-01 2022-03-31 0001724979 rain:UndesignatedCommonStockMember 2021-04-27 2021-04-27 0001724979 us-gaap:NonvotingCommonStockMember 2021-04-27 2021-04-27 0001724979 2021-04-27 0001724979 us-gaap:IPOMember 2021-04-30 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2022-03-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0001724979 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001724979 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0001724979 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001724979 us-gaap:FurnitureAndFixturesMember 2022-03-31 0001724979 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001724979 us-gaap:LeaseholdImprovementsMember 2022-03-31 0001724979 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001724979 us-gaap:ComputerEquipmentMember 2022-03-31 0001724979 us-gaap:ComputerEquipmentMember 2021-12-31 0001724979 us-gaap:IPOMember 2021-04-16 0001724979 2021-04-16 0001724979 rain:UndesignatedPreferredStockMember 2021-04-16 0001724979 rain:UndesignatedCommonStockMember 2021-04-16 0001724979 us-gaap:NonvotingCommonStockMember 2021-04-16 rain:Vote 0001724979 us-gaap:NonvotingCommonStockMember 2022-01-01 2022-03-31 0001724979 us-gaap:NonvotingCommonStockMember srt:MaximumMember 2022-01-01 2022-03-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-12-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-01 2018-04-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-12-01 2018-12-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-30 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-01 2020-09-30 0001724979 rain:SeriesAConvertiblePreferredStockMember 2018-04-01 2022-03-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2020-09-01 2022-03-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001724979 rain:TwoThousandAndEighteenStockIssuancePlanMember 2021-04-15 2021-04-15 0001724979 us-gaap:EmployeeStockOptionMember rain:TwoThousandTwentyOneEquityIncentivePlanMember srt:MaximumMember 2021-04-15 0001724979 us-gaap:EmployeeStockOptionMember rain:TwoThousandAndEighteenStockIssuancePlanMember 2022-03-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-04-15 2021-04-15 0001724979 us-gaap:EmployeeStockOptionMember rain:TwoThousandTwentyOneEquityIncentivePlanMember 2022-01-01 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-12-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2022-01-01 2022-03-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2022-03-31 0001724979 rain:TwoThousandTwentyOneEquityIncentivePlanMember 2021-01-01 2021-12-31 0001724979 rain:EmployeeStockPurchasePlanMember srt:MaximumMember 2021-04-15 0001724979 rain:EmployeeStockPurchasePlanMember 2021-04-15 0001724979 rain:EmployeeStockPurchasePlanMember 2021-04-15 2021-04-15 0001724979 rain:EmployeeStockPurchasePlanMember 2022-01-01 0001724979 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001724979 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001724979 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001724979 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2022-03-31 0001724979 rain:TwoThousandAndTwentyOneEmployeeSharePurchasePlanMember 2022-01-01 2022-03-31 0001724979 us-gaap:EmployeeStockOptionMember 2022-03-31 0001724979 us-gaap:EmployeeStockOptionMember 2021-12-31 0001724979 rain:ReservedForFutureEquityAwardGrantsMember 2022-03-31 0001724979 rain:ReservedForFutureEquityAwardGrantsMember 2021-12-31 0001724979 rain:ReservedForFutureESPPIssuancesMember 2022-03-31 0001724979 rain:ReservedForFutureESPPIssuancesMember 2021-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2022-01-01 2022-03-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2020-09-01 2020-09-30 rain:FamiliesofPatent rain:Trial 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2022-03-03 2022-03-03 rain:Installment 0001724979 rain:DaiichiSankyoLicenseAgreementMember us-gaap:SubsequentEventMember 2022-04-01 2022-04-30 0001724979 rain:DaiichiSankyoLicenseAgreementMember srt:ScenarioForecastMember 2022-04-01 2022-06-30 0001724979 rain:DaiichiSankyoLicenseAgreementMember srt:ScenarioForecastMember 2022-07-01 2022-09-30 0001724979 rain:DaiichiSankyoLicenseAgreementMember srt:ScenarioForecastMember 2022-10-01 2022-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-01-01 2021-03-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2022-03-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-12-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2022-03-01 2022-03-31 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-09-30 0001724979 rain:DaiichiSankyoLicenseAgreementMember 2021-03-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2022-01-01 2022-03-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2022-03-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember 2021-01-01 2021-03-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember srt:MinimumMember 2022-01-01 2022-03-31 0001724979 rain:DrexelUniversityMember rain:DrexelLicenseAgreementMember srt:MaximumMember 2022-01-01 2022-03-31 0001724979 2018-09-30 0001724979 2018-09-01 2018-09-30 0001724979 2020-06-01 2020-06-30 0001724979 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001724979 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001724979 rain:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001724979 rain:SeriesBConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001724979 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period fromto

Commission File Number: 001-40356

 

Rain Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

82-1130967

( State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

8000 Jarvis Avenue, Suite 204

Newark, CA

94560

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (510) 953-5559

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

RAIN

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

  

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes      No  

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.     Yes      No  

As of April 28, 2022, the registrant had 26,529,878 shares of common stock, $0.001 par value per share, outstanding, comprised of 18,802,408 shares of common stock, $0.001 par value per share and 7,727,470 shares of non-voting common stock, $0.001 par value per share.

 

 

 


 

 

 

 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Condensed Financial Statements (Unaudited)

3

 

Condensed Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021

3

 

Condensed Statements of Operations and Comprehensive Loss (Unaudited) for the three months ended March 31, 2022 and 2021

4

 

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) (Unaudited) for the three months ended March 31, 2022 and 2021

5

 

Condensed Statements of Cash Flows (Unaudited) for the three months ended March 31, 2022 and 2021

6

 

Notes to Condensed Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

22

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

32

Item 4.

Controls and Procedures

32

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

34

Item 1A.

Risk Factors

34

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

34

Item 3.

Defaults Upon Senior Securities

34

Item 4.

Mine Safety Disclosures

34

Item 5.

Other Information

34

Item 6.

Exhibits

35

Signatures

36

 

2

 


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Rain Therapeutics Inc.

Condensed Balance Sheets

(In thousands, except share and per share data)

(unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021 (1)

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

21,505

 

 

$

24,780

 

Short-term investments

 

 

101,668

 

 

 

115,438

 

Prepaid and other current assets

 

 

3,658

 

 

 

5,928

 

Total current assets

 

 

126,831

 

 

 

146,146

 

Property and equipment, net

 

 

142

 

 

 

165

 

Operating lease right-of-use asset

 

 

355

 

 

 

386

 

Other assets

 

 

450

 

 

 

443

 

Total assets

 

$

127,778

 

 

$

147,140

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

3,029

 

 

$

6,112

 

Accrued research and development

 

 

5,374

 

 

 

4,349

 

Other accrued liabilities

 

 

4,480

 

 

 

5,694

 

Operating lease liability, current portion

 

 

161

 

 

 

160

 

Total current liabilities

 

 

13,044

 

 

 

16,315

 

Operating lease liability, net of current portion

 

 

219

 

 

 

252

 

Other long-term liabilities

 

 

64

 

 

 

69

 

Total liabilities

 

 

13,327

 

 

 

16,636

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common Stock, $0.001 par value; 250,000,000 shares authorized

     as of March 31, 2022 and December 31, 2021, respectively;

     26,526,878 shares (comprised of 18,799,408 shares of

     common stock and 7,727,470 shares of non-voting common

     stock) and 26,475,812 shares (comprised of 18,748,342 shares

     of common stock and  7,727,470 shares of non-voting common

     stock) issued and  outstanding as of March 31, 2022 and

     December 31, 2021,  respectively

 

 

27

 

 

 

27

 

Additional paid-in capital

 

 

222,171

 

 

 

220,530

 

Accumulated other comprehensive loss

 

 

(389

)

 

 

(89

)

Accumulated deficit

 

 

(107,358

)

 

 

(89,964

)

Total stockholders' equity

 

 

114,451

 

 

 

130,504

 

Total liabilities and stockholders' equity

 

$

127,778

 

 

$

147,140

 

 

(1) The balance sheet at December 31, 2021 has been derived from the audited financial statements included in Rain Therapeutics Inc.’s Annual Report on Form 10-K filed on March 3, 2022.

 

See accompanying notes to financial statements.

3

 


 

Rain Therapeutics Inc.

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(unaudited)

 

 

 

Three Months Ended

March 31,

 

 

 

 

2022

 

 

2021

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

Research and development

 

$

13,555

 

 

$

5,328

 

 

General and administrative

 

 

3,895

 

 

 

1,480

 

 

Total operating expenses

 

 

17,450

 

 

 

6,808

 

 

Loss from operations

 

 

(17,450

)

 

 

(6,808

)

 

Other income:

 

 

 

 

 

 

 

 

 

Interest income

 

 

56

 

 

 

8

 

 

Net loss

 

$

(17,394

)

 

$

(6,800

)

 

Net loss per share, basic and diluted

 

$

(0.66

)

 

$

(1.93

)

 

Weighted-average shares used to compute net loss per share,

     basic and diluted

 

 

26,511,743

 

 

 

3,530,975

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(17,394

)

 

$

(6,800

)

 

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

Unrealized loss on short-term investments

 

 

(300

)

 

 

-

 

 

Comprehensive loss

 

$

(17,694

)

 

$

(6,800

)

 

 

See accompanying notes to financial statements.

4

 


 

Rain Therapeutics Inc.

Condensed Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(In thousands, except share amounts)

(unaudited)

 

 

 

Series A

 

 

Series B

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible Preferred

Stock

 

 

Convertible Preferred

Stock

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Accumulated Other Comprehensive

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Loss

 

 

Equity

 

Balance as of December 31, 2021

 

 

 

 

$

 

 

 

 

 

$

 

 

 

 

26,475,812

 

 

$

27

 

 

$

220,530

 

 

$

(89,964

)

 

$

(89

)

 

$

130,504

 

Exercise of stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24,262

 

 

 

 

 

 

106

 

 

 

 

 

 

 

 

 

106

 

Issuance of common stock from employee stock purchase plan

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

26,804

 

 

 

 

 

 

293

 

 

 

 

 

 

 

 

 

293

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,242

 

 

 

 

 

 

 

 

 

1,242

 

Unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(300

)

 

 

(300

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(17,394

)

 

 

 

 

 

(17,394

)

Balance as of March 31, 2022

 

 

 

 

$

 

 

 

 

 

$

 

 

 

 

26,526,878

 

 

$

27

 

 

$

222,171

 

 

$

(107,358

)

 

$

(389

)

 

$

114,451

 

 

 

 

Series A

 

 

Series B

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible Preferred

Stock

 

 

Convertible Preferred

Stock

 

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Accumulated Other Comprehensive

 

 

Total

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income

 

 

Deficit

 

Balance as of December 31, 2020

 

 

3,731,208

 

 

$

20,147

 

 

 

12,542,198

 

 

$

74,550

 

 

 

 

3,530,975

 

 

$

4

 

 

$

1,149

 

 

$

(38,570

)

 

$

 

 

$

(37,417

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

165

 

 

 

 

 

 

 

 

 

165

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,800

)

 

 

 

 

 

(6,800

)

Balance as of March 31, 2021

 

 

3,731,208

 

 

$

20,147

 

 

 

12,542,198

 

 

$

74,550

 

 

 

 

3,530,975

 

 

$

4

 

 

$

1,314

 

 

$

(45,370

)

 

$

 

 

$

(44,052

)

 

See accompanying notes to financial statements.

5

 


 

Rain Therapeutics Inc.

Condensed Statements of Cash Flows

(In thousands)

(unaudited)

 

 

 

Three Months Ended

March 31,

 

 

 

2022

 

 

2021

 

Operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(17,394

)

 

$

(6,800

)

Adjustments to reconcile net loss to cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization expense

 

 

22

 

 

 

15

 

Stock-based compensation expense

 

 

1,242

 

 

 

165

 

Amortization of premium and accretion of discounts on short-term investments, net

 

 

33

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid and other current assets

 

 

2,271

 

 

 

(40

)

Operating lease right-of-use asset and liability, net

 

 

(1

)

 

 

(19

)

Other assets

 

 

(7

)

 

 

(193

)

Accounts payable

 

 

(3,083

)

 

 

573

 

Accrued research and development

 

 

1,025

 

 

 

576

 

Other accrued liabilities

 

 

(1,218

)

 

 

857

 

Net cash used in operating activities

 

 

(17,110

)

 

 

(4,866

)

 

 

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

 

 

 

Purchases of short-term investments

 

 

(9,514

)

 

 

 

Purchases of property and equipment

 

 

 

 

 

(29

)

Maturities of short-term investments

 

 

22,950

 

 

 

 

 

Net cash provided by (used in) investing activities

 

 

13,436

 

 

 

(29

)

 

 

 

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

 

 

 

Proceeds from the issuance of common stock under the Company's equity incentive plans and employee stock purchase plan

 

 

399

 

 

 

 

Payments of issuance costs related to the initial public offering

 

 

 

 

 

(858

)

Net cash provided by (used in) financing activities

 

 

399

 

 

 

(858

)

Net decrease in cash and cash equivalents

 

 

(3,275

)

 

 

(5,753

)

Cash and cash equivalents at beginning of period

 

 

24,780

 

 

 

58,863

 

Cash and cash equivalents at end of period

 

$

21,505

 

 

$

53,110

 

 

See accompanying notes to financial statements.

6

 


 

Rain Therapeutics Inc.

Notes to Condensed Financial Statements (unaudited)

 

Note 1 – Organization and Nature of Operations

 

Description of Business

Rain Therapeutics Inc. (“Rain” or the “Company”) was incorporated in the state of Delaware in April 2017. Rain is a late-stage precision oncology company developing therapies that target oncogenic drivers for which the Company is able to genetically select patients the Company believes will be most likely to benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of mouse double minute 2, which may be oncogenic in numerous cancers. In addition to milademetan, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The Company operates in one business segment and its principal operations are in the United States, with its headquarters in Newark, California.

Reverse Stock Split

On April 15, 2021 and April 16, 2021, the Company’s board of directors (the “Board of Directors”) and stockholders, respectively, approved an amended and restated certificate of incorporation of the Company to effect a 1-for-1.0799 reverse stock split of the Company’s common stock. The reverse stock split was effected on April 16, 2021. The Company’s outstanding stock options were also adjusted to reflect the 1-for-1.0799 reverse stock split of the Company’s common stock. Accordingly, all common stock and stock options and related per share amounts in these financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion.

Initial Public Offering

On April 27, 2021, the Company completed its initial public offering (“IPO”) in which the Company issued and sold 7,352,941 shares of common stock at a public offering price of $17.00 per share. On May 11, 2021, the Company issued an additional 492,070 shares of common stock in connection with the exercise of the underwriters’ option to purchase additional shares at the public offering price. The Company’s net proceeds from the sale of shares in the IPO, including the sale of shares pursuant to the exercise of the underwriters’ option to purchase additional shares, was $121.5 million, net of underwriting discounts and commissions, and other offering fees.

Immediately prior to the closing of the IPO, 8,344,905 shares of the Company’s convertible preferred stock were exchanged for 7,727,470 shares of non-voting common stock. Upon the closing of the IPO, 7,928,501 shares of the Company’s convertible preferred stock were automatically converted into 7,341,860 shares of common stock. Following the IPO, there were no shares of convertible preferred stock outstanding.

Basis of Presentation

The accompanying interim unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) related to a quarterly report on Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). The year-end balance sheet data was derived from the Company’s audited financial statements but does not include all disclosures required by GAAP. These condensed financial statements should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2021 included in the Company’s Annual Report on Form 10-K, filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act). The unaudited financial information for the interim periods presented herein reflects all adjustments which, in the opinion of management, are necessary for a fair presentation of the financial condition and results of operation for the periods presented, with such adjustments consisting only of normal recurring adjustments.

Liquidity and Capital Resources

The Company has devoted substantially all of its efforts to drug discovery and development, raising capital and building operations. The Company has a limited operating history and has not generated any revenue since its inception,

7

 


 

and the sales and income potential of the Company’s business is unproven. The Company has incurred net losses and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development of its product candidates. From inception through March 31, 2022, the Company has funded its operations through net proceeds from its IPO in April 2021, and the issuance of convertible promissory notes and convertible preferred stock.

The accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern. Management believes that the Company’s current cash, cash equivalents and short-term investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.

Note 2 – Summary of Significant Accounting Policies

Use of Estimates

The preparation of the Company’s condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent liabilities in the Company’s condensed financial statements and accompanying notes. The most significant estimate in the Company’s condensed financial statements relates to the clinical trial expense accruals. Management evaluates its estimates on an ongoing basis. Although these estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents include commercial paper, readily available money market and checking accounts.

Available-for-Sale Investments

The Company holds investment grade securities consisting of money market funds, commercial paper, corporate debt securities, U.S. government securities and U.S. agency bonds, classified as available-for-sale (“AFS”) securities at the time of purchase, since it is the Company’s intent that these investments be available for current operations. The Company has classified all of its AFS securities as current assets on the condensed balance sheets even though the stated maturity date may be one year or more beyond the current condensed balance sheet date, which reflects management’s intention to use the proceeds from sales of these securities to fund its operations, as necessary.

The Company carries these securities at fair value and reports unrealized gains and losses, if any, as a separate component of accumulated other comprehensive loss. The cost of debt securities is adjusted for amortization of purchase premiums and accretion of discounts to maturity. Such amortization and accretion are included in interest income in the condensed statements of operations and comprehensive loss. Realized gains and losses on sales of securities are determined using the specific identification method and recorded in other income (expense), net in the condensed statement of operations and comprehensive loss.

Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. The Company consults with its investment managers and considers available quantitative and qualitative evidence in evaluating potential impairment of its investments on a quarterly basis. If the cost of an individual investment exceeds its fair value, the Company evaluates among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and the Company’s intent and ability to hold the investment. Once an impairment is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. Declines in the value of AFS securities determined to be other than temporary are included in other income (expense), net.

Deferred Offering Costs

The Company capitalized deferred offering costs consisting of all direct and incremental legal, professional, accounting and other third-party fees incurred in connection with the Company’s IPO. Upon the completion of the IPO in April 2021, the total deferred offering costs of $2.5 million were reclassified to additional paid-in capital on the condensed balance sheets.

8

 


 

Research and Development Costs

Research and development costs primarily consist of costs associated with the Company’s research and development activities, including its drug discovery efforts, and the preclinical and clinical development of its product candidates. Research and development costs are expensed as incurred.

Preclinical Studies and Clinical Trial Accruals

The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, clinical research organizations and clinical site agreements in connection with conducting preclinical activities and clinical trials. The financial terms of these contracts are subject to negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects preclinical study and clinical trial expenses in its condensed financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study or clinical trial as measured by the timing of various aspects of the preclinical study, clinical trial or related activities. The Company determines accrual and prepaid estimates through review of the underlying contracts along with preparation of financial models taking into account correspondence with clinical and other key personnel and third-party service providers as to the progress of preclinical studies, clinical trials or other services being conducted. During the course of a preclinical study or clinical trial, the Company adjusts its expense recognition if actual results differ from its estimates. To date, the Company has not experienced any material differences between accrued costs and actual costs incurred.

Stock-Based Compensation

Stock-based compensation expense represents the grant date fair value of equity awards recognized over the requisite service period of the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. Prior to the IPO, the exercise price for all stock options granted was at the estimated fair value of the underlying common stock as determined on the date of grant by the Company’s Board of Directors.

Income Taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.

Effective January 1, 2022, we adopted ASU 2019-12 - Simplifying the Accounting for Income Taxes. The adoption of this standard did not impact the Company’s condensed financial statements or related disclosures.

Comprehensive Loss

Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive loss includes unrealized gains / losses from short-term investments.

9

 


 

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted-average number of shares of common stock plus the potential dilutive effects of potential dilutive securities outstanding during the period. Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is antidilutive. The Company’s potentially dilutive securities, which include convertible preferred stock, shares from the 2021 Employee Stock Purchase Plan (the “ESPP”), and outstanding stock options under the Company’s equity incentive plan, have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For the periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.

Recent Developments Regarding the COVID-19 Pandemic

Efforts to control the outbreak of COVID-19 have resulted in challenges to businesses and facilities in various industries around the world, including disruptions to the global economy and supply chains. To date, COVID-19 has not had a material impact on the Company’s expenditures.

The Company is unable to predict the ultimate effects of COVID-19 on the U.S. or global economy or its operations. The Company continues to monitor developments affecting its workforce, suppliers, and operations. The extent of the impact of COVID-19 will depend on its duration, actions by government authorities, and impacts on the Company’s employees, or vendors. These developments are continuously evolving, and the Company cannot predict whether COVID-19 will have a material impact on its financial condition, results of operations or cash flows.

Recent Accounting Pronouncements

Financial Instruments. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are recorded. The guidance is effective for the Company beginning on January 1, 2023, with early adoption permitted. The Company does not anticipate that the adoption of ASU 2016-13 will have a significant impact on its condensed financial statements or the related disclosures.

There were no other significant updates to the recently issued accounting standards other than as disclosed herein for the three months ended March 31, 2022. Although there are several other new accounting pronouncements issued or proposed by the FASB, based on the Company’s preliminary assessment, the Company does not believe any of those accounting pronouncements have had or will have a material impact on its financial position or operating results.

Note 3 – Fair Value Measurements

The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The carrying amounts of cash, prepaid expenses and other current assets, deferred offering costs, accounts payable, accrued research and development and other current liabilities are reasonable estimates of their fair value due to the short-term nature of these accounts.

The Company’s money market funds under cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative

10

 


 

pricing sources with reasonable levels of price transparency. There were no transfers between levels of the fair value hierarchy during the three months ended March 31, 2022.

The following table summarizes financial assets that the Company measured at fair value on a recurring basis, classified in accordance with the fair value hierarchy (in thousands):

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of March 31, 2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

10,252

 

 

$

 

 

$

 

 

$

10,252

 

Commercial paper

 

 

 

 

 

73,558

 

 

 

 

 

 

73,558

 

U.S. government securities

 

 

27,640

 

 

 

 

 

 

 

 

 

27,640

 

U.S. agency bonds

 

 

 

 

 

8,465

 

 

 

 

 

 

8,465

 

Corporate debt securities

 

 

 

 

 

2,001

 

 

 

 

 

 

2,001

 

Total cash equivalents and short-term investments

 

$

37,892

 

 

$

84,024

 

 

$

 

 

$

121,916

 

Reported as:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents (includes cash of $1,257)

 

 

 

 

 

 

 

 

 

 

 

 

 

$

21,505

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

101,668

 

Total cash, cash equivalents and short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

$

123,173

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at Reporting Date Using:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of December 31, 2021:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

10,585

 

 

$

 

 

$

 

 

$

10,585

 

Commercial paper

 

 

 

 

 

84,616

 

 

 

 

 

 

84,616

 

U.S. government securities

 

 

27,824

 

 

 

 

 

 

 

 

 

 

27,824

 

U.S. agency bonds

 

 

 

 

 

8,531

 

 

 

 

 

 

8,531

 

Corporate debt securities

 

 

 

 

 

8,265

 

 

 

 

 

 

8,265

 

Total cash equivalents and short-term investments

 

$

38,409

 

 

$

101,412

 

 

$

 

 

$

139,821

 

Reported as:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents (includes cash of $397)

 

 

 

 

 

 

 

 

 

 

 

 

 

$

24,780

 

Short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

115,438

 

Total cash, cash equivalents and short-term investments

 

 

 

 

 

 

 

 

 

 

 

 

 

$

140,218

 

Note 4 – Investments

Financial assets measured at fair value on a recurring basis consist of the Company’s cash equivalents and AFS securities. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, and bids and/or offers.

Investments are classified as Level 1 within the fair value hierarchy if their quoted prices are available in active markets for identical securities. Investments in money market funds and U.S. government securities were classified as Level 1 instruments.

Investments in commercial paper, corporate debt securities and U.S. agency bonds are valued using Level 2 inputs. The Company classifies investments within Level 2 if the investments are valued using model driven valuations using observable inputs such as quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. Investments are held by custodians who obtain investment prices from a third-party pricing provider that incorporates standard inputs in various asset price models.

11

 


 

The following table summarizes, by major types of cash equivalents, and investments that are measured at fair value on a recurring basis (in thousands):

 

 

 

March 31, 2022

 

 

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

Money market funds

 

$

10,252

 

 

$

 

 

$

 

 

$

10,252

 

Commercial paper

 

 

73,667

 

 

 

 

 

(108

)

 

 

73,559

 

U.S. government securities

 

 

27,838

 

 

 

 

 

(199

)

 

 

27,639

 

U.S. agency bonds

 

 

8,530

 

 

 

 

 

(65

)

 

 

8,465

 

Corporate debt securities

 

 

2,018

 

 

 

 

 

(17

)

 

 

2,001

 

Cash equivalents and investments

 

$

122,305

 

 

$

 

 

$

(389

)

 

$

121,916

 

 

 

 

December 31, 2021

 

 

 

Amortized

Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Estimated

Fair Value

 

Money market funds